Clinical trials: Residual Disease
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia.
- Trial name
- NCT03737955
- Testing
- Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Leukemia, Myeloid
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine.
- Trial name
- NCT04748848
- Testing
- CC-90011, Venetoclax, Azacitidine
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Osteoarthritis, Hip, Femoroacetabular Impingement
Early Feasibility Study of Cartilage Defect Repair
Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed…
- Conditions
- Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Legg-Calvé-Perthes Disease
- Trial name
- NCT06823089
- Testing
- ReNew Hip Implant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cytex Therapeutics, Inc.
B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia)
BLinatumomab and iNKT in Relapsed B-Cell ALL
This is an open-label, single-arm pilot study evaluating agenT-797, an invariant natural killer T-cell (iNKT) therapy, in combination with routine clinical care blinatumomab in subjects with Philadelphia chromosome-negative…
- Conditions
- B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
- Trial name
- BLINK B-ALL (NCT07869368)
- Testing
- Invariant Natural Killer T Cell Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colon Adenocarcinoma, Stage I Colon Cancer
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation…
- Conditions
- Colon Adenocarcinoma, Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- ADX-DRIVER-CRC (NCT07795528)
- Testing
- Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Ruijin Hospital
Diabetes Mellitus
Residual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
Comparison of residual gastric volume measure by ultrasounds between diabetic and non-diabetic patients scheduled for elective surgery
- Trial name
- NCT05435157
- Where
- Spain
- Volunteers
- 592 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Chronic Myeloid Leukemia
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy for haematological malignancies.
- Trial name
- NCT00815321
- Testing
- Autologous CIK cell infusion
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer
SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality
After endoscopic removal of a colorectal polyp that harbors (unexpected) adenocarcinoma, pathology usually can not guarantee a radical resection from an oncological point of view.
- Trial name
- SCAPURA (NCT02328664)
- Testing
- Flexible sigmoidoscopy or colonoscopy
- Where
- 36 sites in Netherlands
- Volunteers
- 246 people
- Sponsor
- Dr. Frank ter Borg MD PhD
Hyperhidrosis, Residual Limbs
Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users
The aim of the present pilot study is to evaluate the effect of antiperspirant to treat residual limb hyperhidrosis with the emphasis on the utility of the iodine-starch test to identify the location of the sweating.
- Trial name
- NCT05501444
- Testing
- Topical antiperspirant
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Sophies Minde Ortopedi
Hyperhidrosis
Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2
The objective is to establish an evidence base for a hyperhidrosis treatment algorithm in amputees. This project will address a problem that has troubled Service members, Veterans, and civilians with amputations for decades…
- Trial name
- NCT03416348
- Testing
- Aluminum Chloride 20% (deodorant), Alcohol
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Utah
Colorectal Cancer
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
- Trial name
- MRD (NCT06398743)
- Testing
- MRD
- Where
- 22 sites in Israel, Italy and 3 more
- Volunteers
- 416 people
- Sponsor
- Exact Sciences Corporation
Schizophrenia
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.
- Trial name
- NCT00611806
- Testing
- Folic Acid, B12
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior…
- Trial name
- NCT05457049
- Testing
- Molecular residual disease test
- Where
- 5 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Fasting, Anesthesia
Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia
The safety implications of prolonged fasting in young children prior to general anaesthesia are well described. Current UK guidance recommends a fasting time of 6 hours for formula milk prior to general anaesthesia.
- Conditions
- Fasting, Anesthesia, Pediatric ALL
- Trial name
- NCT06067321
- Testing
- abdominal ultrasound, insertion of naso-gastric tube
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Stage II-III Gastric Cancer
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
This is a single-arm, interventional study to explore the feasibility of circulating tumor DNA (ctDNA)-MRD testing to guide postoperative adjuvant treatment strategies in patients with stage II-III gastric cancer.
- Trial name
- NCT06157216
- Testing
- MRD-guided therapy
- Where
- 5 sites in China
- Volunteers
- 65 people
- Sponsor
- Qilu Hospital of Shandong University
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Kidney Disease (Stages 4 and 5), Chronic Kidney Disease 5D
The Practicality and Utility of Measured vs Estimated GFR in adCKD
The goal of this observational study is to assess if new ways of measuring kidney function can better predict when individuals will become symptomatic due to kidney failure, and whether residual kidney function can be accurately…
- Trial name
- NCT07450534
- Testing
- Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Manchester University NHS Foundation Trust
Breast Cancer
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have…
- Trial name
- FLAMINGO-01 (NCT05232916)
- Testing
- GLSI-100
- Where
- 179 sites in United States, Belgium and 8 more
- Volunteers
- 2,250 people
- Sponsor
- Greenwich LifeSciences, Inc.
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Depression, Anxiety
Adjunct Interpersonally Focused Psychodynamic Group Psychotherapy for Residual Depression Symptoms
Depression and anxiety disorders, even when treated according to standard of care consisting of individual treatment with medication and/or therapy, can be associated with significant residual impact on quality of life.
- Trial name
- NCT02449499
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.